Biotech Week
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Biotech Week
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Adverse Drug Reaction
Patient toxicity from 5-FU chemotherapy predicted by OPRT gene polymorphism
September 20th, 2006
Orotate phosphoribosyltransferase (OPRT) Gly(213) Ala polymorphism could help predict toxicity in patients receiving bolus 5-fluorouracil (5-FU) chemotherapy. "We investigated whether the determination of OPRT and thymidylate synthase (TYMS) polymorphisms could predict the toxicity of 5-FU in colorectal cancer patients. The determination of OPRT and TYMS genotypes were done in genomic DNA extracted from blood by PCR amplification in 69 patients treated with bolus 5-FU as adjuvant chemotherapy," scientists in Japan reported. "Associations between these polymorphisms and toxicity were evaluated retrospectively. The Ala allele in OPRT Gly(213)Ala...
Source: Biotech Week (2006-09-20)
|
